By PPN News Staff
Pivotal data from the phase 3 XTEND-Kids study evaluating antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein (Altuviiio, Sanofi) as a once-weekly prophylaxis reduced bleeding episodes among younger children with severe hemophilia A, according to results from the 2023 annual meeting of the International Society on Thrombosis and Haemostasis, in Montreal.
The oral presentation detailed results confirming Fc-VWF-XTEN fusion protein met the primary end point with no